Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




BRCA2 Variant Analysis Offers Insights Into Breast Cancer Risk and Treatment

By LabMedica International staff writers
Posted on 20 Nov 2026

Assessing inherited breast cancer risk can be challenging because different genetic variants may carry varying levels of risk. More...

Harmful BRCA2 variants are generally associated with a 50% to 70% lifetime risk of breast cancer, influencing decisions about screening and prevention. However, new findings suggest that certain BRCA2 variants may confer a more moderate risk, highlighting the importance of more individualized genetic risk assessment.

Researchers at Mayo Clinic identified a group of hypomorphic BRCA2 variants associated with reduced penetrance, meaning they confer a lower risk of breast cancer than typical pathogenic BRCA2 variants. The study focused on 70 genetic variants that partially impair BRCA2 function rather than completely disrupting it. By examining their effects on gene activity alongside hereditary cancer testing data from a large patient population, researchers investigated how these variants influence inherited breast cancer risk.

The analysis estimated that individuals carrying these specific BRCA2 variants have a 20% to 25% lifetime risk of developing breast cancer, substantially lower than the risk generally associated with conventional pathogenic BRCA2 mutations. These findings suggest that variant-specific risk assessment could help clinicians tailor screening and prevention strategies more precisely. Although carriers may still qualify for regular mammography and breast magnetic resonance imaging (MRI), more accurate risk estimates could help inform decisions about preventive measures, including risk-reducing surgery.

The researchers also investigated whether tumors associated with hypomorphic BRCA2 variants might respond to PARP inhibitors, a class of targeted therapies that interfere with DNA repair mechanisms in cancer cells. The findings suggest that some tumors carrying these variants may retain sensitivity to PARP inhibition, potentially expanding treatment considerations for affected patients. However, tumor testing would be important to determine whether these therapies are appropriate in individual cases.

Published in Nature Communications on November 17, 2026, the study was conducted in collaboration with Ambry Genetics. Building on these findings, researchers are continuing to identify and characterize hypomorphic variants in both BRCA1 and BRCA2 to better understand their effects on inherited cancer risk. This work could help refine genetic counseling, personalize cancer prevention strategies, and inform treatment decisions for individuals carrying these variants.

“This shows that not all harmful BRCA2 variants carry the same level of breast cancer risk. Understanding these differences could help us better match cancer prevention and screening strategies to an individual's actual risk,” said Fergus Couch, Ph.D., a breast cancer researcher at Mayo Clinic Comprehensive Cancer Center. 

“Women and men who inherit these variants should benefit from risk management strategies tailored to the level of risk associated with the specific variant,” said Couch.

Related Links
Mayo Clinic Comprehensive Cancer Center


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New evidence now questions whether a single stool-test cutoff should be applied uniformly across all age groups.(Photo courtesy of Paul Maguire - Adobe Stock)

Study Questions Uniform Stool-Test Cutoff Across Age Groups

Colorectal cancer remains a major clinical challenge, ranking as the fourth most common cancer and the second-leading cause of cancer death in the U.K. Early-onset colorectal cancer, defined as diagnosis... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.